Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment. We will measure how many of these patients complete their participation in this program.
Checked against the public recordLast updated Mar 20, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Interventions being studied
- Behavioral: Walk With Ease Program; Other: Collect Blood, GA and Other Survey Tools
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * ≥60 years of age, male or female * Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer diagnosis, then the most recent diagnosis); Stage I, II or III lung cancer, or Stage II or III colon cancer * Scheduled to begin a chemotherapy (or concomitant chemoradiotherapy) regimen that will last at least 6 weeks in duration * English speaking * IRB approved, signed written informed consent * Approval from their treating physician to engage in moderate-intensity physical activity * Patient-assessed ability to walk and engage in moderate physical activity * Willing and able to meet all study requirements. Exclusion Criteria: * One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention * Cancer surgery scheduled within the study period * Unable to walk or engage in moderate-intensity physical activity
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of North Carolina Cancer HospitalChapel Hill, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 20, 2024. Always confirm current availability with the study team.